All patients (n = 660) | Unmatched (n = 349) | Matched (n = 224)a | ||||||
---|---|---|---|---|---|---|---|---|
C20 | C25 | SD score | C20 | C25 | SD score | |||
N | 660 | 190 | 159 | – | 112 | 112 | – | |
Age, years | 70.0 (43–91) | 71.0 (51–89) | 69.0 (44–83) | 0.271 | 69.5 (51–89) | 70.0 (51–83) | 0.051 | |
Body surface area, m2 | 1.65 (1.26–2.20) | 1.63 (1.26–2.02) | 1.65 (1.30–2.20) | 0.046 | 1.66 (1.26–2.02) | 1.66 (1.30–2.20) | 0.016 | |
Duration of disease, years | 4.16 (0.5–19.8) | 4.71 (1.0–17.5) | 3.85 (0.8–19.8) | 0.059 | 4.10 (1.0–17.5) | 3.71 (0.8–19.8) | 0.069 | |
Gleason score | 2–7 | 104 (15.8) | 28 (14.7) | 27 (17.0) | 0.064 | 14 (12.5) | 15 (13.4) | 0.025 |
8–10 | 516 (78.2) | 149 (78.4) | 125 (78.6) | 98 (87.5) | 97 (86.6) | |||
TNM stage | T1 + T2 | 113 (17.1) | 37 (19.5) | 30 (18.9) | 0.013 | 20 (17.9) | 22 (19.6) | 0.045 |
T3 + T4 + TX | 538 (81.5) | 149 (78.4) | 128 (80.5) | 92 (82.1) | 90 (80.4) | |||
N0 | 297 (45.0) | 94 (49.5) | 72 (45.3) | 0.068 | 50 (44.6) | 53 (47.3) | 0.054 | |
N1 + NX | 359 (54.4) | 93 (49.0) | 86 (54.1) | 62 (55.4) | 59 (52.7) | |||
M0 | 190 (28.8) | 58 (30.5) | 45 (28.3) | 0.054 | 32 (28.6) | 30 (26.8) | 0.040 | |
M1 + MX | 466 (70.6) | 131 (69.0) | 112 (70.4) | 80 (71.4) | 82 (73.2) | |||
ECOG PS | 0 | 412 (62.4) | 109 (57.4) | 100 (62.9) | 0.126 | 68 (60.7) | 67 (59.8) | 0.018 |
≥1 | 247 (37.4) | 81 (42.6) | 58 (36.5) | 44 (39.3) | 45 (40.2) | |||
PSA (at baseline), ng/mL | 164.9 (0.0–16,697.2) | 146.1 (0.0–10,027.1) | 173.2 (0.3–9892.3) | 0.110 | 120.8 (0.0–4286.0) | 187.6 (0.3–9892.3) | 0.068 | |
Previous medical history | 202 (30.61) | 65 (34.2) | 44 (27.7) | 0.159 | 36 (32.1) | 37 (33.0) | 0.019 | |
Complications | 275 (41.67) | 82 (43.2) | 61 (38.4) | 0.146 | 42 (37.5) | 43 (38.4) | 0.018 | |
Previous treatments | ||||||||
Radical local excision | 212 (32.12) | 62 (32.6) | 49 (30.8) | 0.061 | 31 (27.7) | 33 (29.5) | 0.039 | |
Switch from docetaxel | 114 (17.27) | 38 (20.0) | 26 (16.4) | 0.172 | 21 (18.8) | 21 (18.8) | 0.000 | |
New-generation AR inhibitorsb | ||||||||
0 or 1 agents | 340 (51.5) | 96 (50.5) | 89 (56.0) | 0.010 | 60 (53.6) | 59 (52.7) | 0.018 | |
2 agents | 319 (48.3) | 94 (49.5) | 70 (44.0) | 52 (46.4) | 53 (47.3) | |||
Docetaxel chemotherapy | 630 (95.5) | 186 (97.9) | 154 (96.9) | 0.070 | 112 (100) | 112 (100) | 0.086 | |
Docetaxel treatment cycles | 9.0 (1–143) | 9.5 (1–47) | 9.0 (1–52) | 10.0 (1–47) | 8.0 (1–38) | |||
Reason for discontinuing docetaxel | PD | 534 (80.9) | 161 (84.7) | 130 (81.8) | 0.085 | 93 (83.0) | 92 (82.1) | 0.024 |
AE/other | 108 (16.4) | 29 (15.3) | 26 (16.4) | 19 (17.0) | 20 (17.9) | |||
Palliative radiation therapy | 197 (29.8) | 69 (36.3) | 47 (29.6) | 0.182 | 36 (32.1) | 34 (30.4) | 0.038 |